Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …

Cancer cells undergo metabolic reprogramming and switch to a 'glycolysis-
dominant'metabolic profile to promote their survival and meet their requirements for energy …

Lipid metabolic reprogramming is involved in mediating tamoxifen (TAM) response in breast
cancer cells. Published microarray data indicated that ATP citrate lyase (ACLY) is …

Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability
in most patients with estrogen receptor positive breast cancers (ER+ BC). By genomic and …

The microenvironment influences cancer drug response and sustains resistance to
therapies targeting receptor-tyrosine kinases. However, if and how the tumor …

Energy deprivation is a frequent adverse event in tumors that is caused by mutations,
malperfusion, hypoxia, and nutrition deficit. The resulting bioenergetic stress leads to …

Cancer treatment with either standard chemotherapy or targeted agents often results in the
emergence of drug-refractory cell populations, ultimately leading to therapy failure. The …

Local acidification of stroma is proposed to favour pre-metastatic niche formation but the
mechanism of initiation is unclear. We investigated whether Human Melanoma-derived …

Background Tamoxifen treatment of estrogen receptor (ER)-positive breast cancer reduces
mortality by 31%. However, over half of advanced ER-positive breast cancers are …

Acquired resistance to tyrosine kinase inhibitors (TKIs) is the major obstacle to improve
clinical efficacy in cancer patients. The epithelial-stromal interaction in tumor …